Trial Profile
Second line therapy with low dose fotemustine in progressive malignant gliomas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2012
Price :
$35
*
At a glance
- Drugs Fotemustine (Primary)
- Indications Glioma
- Focus Pharmacogenomic; Therapeutic Use
- 06 Jul 2011 New trial record